Search

Your search keyword '"Ekeke, O.N."' showing total 13 results
Start Over Author "Ekeke, O.N."
13 results on '"Ekeke, O.N."'

2. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Author

Gillessen, S. Bossi, A. Davis, I.D. de Bono, J. Fizazi, K. James, N.D. Mottet, N. Shore, N. Small, E. Smith, M. Sweeney, C.J. Tombal, B. Antonarakis, E.S. Aparicio, A.M. Armstrong, A.J. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Blanchard, P. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Castellano, D. Castro, E. Cheng, H.H. Chi, K.N. Chowdhury, S. Clarke, C.S. Clarke, N. Daugaard, G. De Santis, M. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fonteyne, V. Fossati, N. Frydenberg, M. George, D. Gleave, M. Gravis, G. Halabi, S. Heinrich, D. Herrmann, K. Higano, C. Hofman, M.S. Horvath, L.G. Hussain, M. Jereczek-Fossa, B.A. Jones, R. Kanesvaran, R. Kellokumpu-Lehtinen, P.-L. Khauli, R.B. Klotz, L. Kramer, G. Leibowitz, R. Logothetis, C. Mahal, B. Maluf, F. Mateo, J. Matheson, D. Mehra, N. Merseburger, A. Morgans, A.K. Morris, M.J. Mrabti, H. Mukherji, D. Murphy, D.G. Murthy, V. Nguyen, P.L. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Pezaro, C.J. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M.A. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Sharifi, N. Skoneczna, I. Soule, H. Spratt, D.E. Srinivas, S. Sternberg, C.N. Steuber, T. Suzuki, H. Sydes, M.R. Taplin, M.-E. Tilki, D. Türkeri, L. Turco, F. Uemura, H. Uemura, H. Ürün, Y. Vale, C.L. van Oort, I. Vapiwala, N. Walz, J. Yamoah, K. Ye, D. Yu, E.Y. Zapatero, A. Zilli, T. Omlin, A. and Gillessen, S. Bossi, A. Davis, I.D. de Bono, J. Fizazi, K. James, N.D. Mottet, N. Shore, N. Small, E. Smith, M. Sweeney, C.J. Tombal, B. Antonarakis, E.S. Aparicio, A.M. Armstrong, A.J. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Blanchard, P. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Castellano, D. Castro, E. Cheng, H.H. Chi, K.N. Chowdhury, S. Clarke, C.S. Clarke, N. Daugaard, G. De Santis, M. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fonteyne, V. Fossati, N. Frydenberg, M. George, D. Gleave, M. Gravis, G. Halabi, S. Heinrich, D. Herrmann, K. Higano, C. Hofman, M.S. Horvath, L.G. Hussain, M. Jereczek-Fossa, B.A. Jones, R. Kanesvaran, R. Kellokumpu-Lehtinen, P.-L. Khauli, R.B. Klotz, L. Kramer, G. Leibowitz, R. Logothetis, C. Mahal, B. Maluf, F. Mateo, J. Matheson, D. Mehra, N. Merseburger, A. Morgans, A.K. Morris, M.J. Mrabti, H. Mukherji, D. Murphy, D.G. Murthy, V. Nguyen, P.L. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Pezaro, C.J. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M.A. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Sharifi, N. Skoneczna, I. Soule, H. Spratt, D.E. Srinivas, S. Sternberg, C.N. Steuber, T. Suzuki, H. Sydes, M.R. Taplin, M.-E. Tilki, D. Türkeri, L. Turco, F. Uemura, H. Uemura, H. Ürün, Y. Vale, C.L. van Oort, I. Vapiwala, N. Walz, J. Yamoah, K. Ye, D. Yu, E.Y. Zapatero, A. Zilli, T. Omlin, A.

Abstract

Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in daily clinical practise. The 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) addressed some questions in these areas to supplement guidelines that mostly are based on level 1 evidence. Objective: To present the voting results of the APCCC 2022. Design, setting, and participants: The experts voted on controversial questions where high-level evidence is mostly lacking: locally advanced prostate cancer; biochemical recurrence after local treatment; metastatic hormone-sensitive, non-metastatic, and metastatic castration-resistant prostate cancer; oligometastatic prostate cancer; and managing side effects of hormonal therapy. A panel of 105 international prostate cancer experts voted on the consensus questions. Outcome measurements and statistical analysis: The panel voted on 198 pre-defined questions, which were developed by 117 voting and non-voting panel members prior to the conference following a modified Delphi process. A total of 116 questions on metastatic and/or castration-resistant prostate cancer are discussed in this manuscript. In 2022, the voting was done by a web-based survey because of COVID-19 restrictions. Results and limitations: The voting reflects the expert opinion of these panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results are reported in the supplementary material. We report here on topics in metastatic, hormone-sensitive prostate cancer (mHSPC), non-metastatic, castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and oligometastatic an

Published
2023

3. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Gillessen, S. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C.S. Clarke, N. Davis, I.D. de Bono, J.S. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D.E. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M.R. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Omlin, A. and Gillessen, S. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C.S. Clarke, N. Davis, I.D. de Bono, J.S. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D.E. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M.R. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Omlin, A.

Abstract

Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: To present the voting results from APCCC 2021. Design, setting, and participants: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical eviden

Published
2022

4. Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11] (European Urology (2022) 82(1) (6–11), (S0302283822016505), (10.1016/j.eururo.2022.02.010))

Author

Turco, F. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C. Clarke, N. Davis, I.D. de Bono, J. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ekeke, O.N. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Gillessen, S. Omlin, A. and Turco, F. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C. Clarke, N. Davis, I.D. de Bono, J. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ekeke, O.N. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Gillessen, S. Omlin, A.

Abstract

The authors regret that Axel Heidenreich was added to the author list in error. The author list is now corrected as above, however the affiliations of remaining authors have been retained. The authors would like to apologise for any inconvenience caused. © 2022 The Author(s)

Published
2022

5. Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Tilki, Derya, Gillessen, S.; Armstron, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.S.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Ekeke, O.N.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I., Yamoah, K.; Ye, D.; Zapatero, A.; Omlin, A., Koç University Hospital, School of Medicine, Tilki, Derya, Gillessen, S.; Armstron, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.S.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Ekeke, O.N.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I., Yamoah, K.; Ye, D.; Zapatero, A.; Omlin, A., Koç University Hospital, and School of Medicine

Abstract

Background: innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: to present the voting results from APCCC 2021. Design, setting, and participants: the experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: the voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: these voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical eviden, National Health and Medical Research Council (NHMRC) Practitioner Fellowship; Prostate Cancer Foundation; Peter MacCallum Foundation; NHMRC Investigator Grant

Published
2022

6. What experts think about prostate cancer management during the COVID-19 pandemic: report from The Advanced Prostate Cancer Consensus Conference 2021

Author

Tilki, Derya, Turco, F.; Armstrong, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ekeke, O.N.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.-E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I.; Yamoah, K.; Ye, D.; Zapatero, A.; Gillessen, S.; Omlin, A., Koç University Hospital, School of Medicine, Tilki, Derya, Turco, F.; Armstrong, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ekeke, O.N.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.-E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I.; Yamoah, K.; Ye, D.; Zapatero, A.; Gillessen, S.; Omlin, A., Koç University Hospital, and School of Medicine

Abstract

Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients., NA

Published
2022

7. Impediments to salvage of the testis after torsion in a Nigerian tertiary hospital

Author

Ekeke, O.N. and Abhulimen, V

Abstract

Background: Testicular torsion is fraught with the risk of losing the testis if prompt surgical intervention is not instituted. The salvage rates for testis after torsion have been found to vary across the globe.Objective: To determine factors affecting the salvage rate of testis following testicular torsion at the University of Port Harcourt Teaching Hospital (UPTH).Design: A prospective descriptive studySetting: University of Port Harcourt Teaching HospitalSubjects: Sixty eight patients who presented with testicular torsion in our hospital from between 2012 and 2015.Intervention: Detorsion and orchidopexy for viable testis. Orchidectomy for gangrenous testis.Main outcome measures: Size of testis after orchidopexy.Results: Sixty-eight patients were treated within the period. The mean age of the patients was 24.6 ± 5.5years. Most patients (n=44; 64.7%) presented between the ages of 21 to 30years. The most common presenting complaint was testicular pain (n=64; 94.12%). Only six patients (8.82%) presented within 6 hours. Eighteen patients (26.47%) first presented to patent medical attendants. Thirty-three patients (48.53%) presented with acute testicular torsion. Thirty-two patients (47.06%) had orchidectomy while 36(52.94%) had orchidopexy. Thirty-two (47.06%) had immediate testicular loss, while twenty-four (35.29%) had satisfactory outcome. Factors associated with testicular loss were presentation after 24hours (p=0.001), and initial treatment by a patent medical attendant and general medical practitioners.Conclusion: Low salvage rate after testicular torsion due to delayed presentation to appropriate health facility was noted in Port Harcourt. Health education and increased awareness even amongst doctors would help improve the salvage rate.

Published
2018

8. Sero-Prevalence of anti-sperm anti-bodies in infertile males in Port Harcourt, Nigeria

Author

Emeghe, I.N. and Ekeke, O.N.

Abstract

Background: Infertility is a serious health challenge which causes distress to the couples especially; in Africa. The cause of infertility is multifactorial. Immunological infertility is said to be one of the major causes of unexplained infertility in men. Anti-sperm anti-bodies can be used as an immunological marker of infertility.Objective: To determine the sero-prevalence of anti-sperm anti-bodies in Port Harcourt.Design: A cross sectional study.Setting: Three hospitals in Port Harcourt, Nigeria.Subjects: Ninety men who presented with infertility.Outcome: Presence of anti-sperm anti-bodies.Results: The results obtained showed that the modal age group for infertile males was 40-49 years. Mean duration of infertility was 5.54±2.34 years. Sixty nine patients (76.67%) had primary infertility, 60% had previous sexually transmitted infections, 65.23% had low sperm counts, 88.46% had abnormal sperm motility and anti-sperm anti-bodies were detected in 26.67%. Presence of antisperm anti-bodies were associated with age ≥ 40 years, previous history of sexually transmitted infections, duration of infertility, and abnormal sperm motility. There was no association between hormone profile and presence of anti-sperm anti-bodies.Conclusion: Anti-sperm anti-bodies are fairly common in Port Harcourt; and immunological factors may contribute to infertility in male patients of the sub-region.

Published
2017

9. Surgical inpatient cancer-related mortality in a Nigerian tertiary hospital

Author

Ekeke, O.N., Igwe, P.O., and Okonta, K.E.

Abstract

Background: Cancer is a distressing condition that imposes so much physical, psychological and economic burden on the patients. Knowledge of the mortality pattern of cancers in any institution will enable the development of tailored preventive and therapeutic strategies.Aim: To present the cancer mortality patterns of University of Port Harcourt Teaching Hospital (UPTH). Methods: A retrospective study of all patients who died from cancer during admission into the surgical wards of UPTH from 2007 to 2012. Data on demography and events leading to death were collected from all surgical wards, the emergency unit, surgical outpatients and theatre records. The data were analyzed using SPSS version 16.0. Results: A total of 171(32.4%) cancer-related deaths of 527 mortalities occurred among the 8230 patients admitted giving a mortality rate of 2.1%. One hundred and eight (63.2 %) were male. The yearly mortality rate were as follows : 2007 (9.4 %) ; 2008 (9.4 %) ; 2009 (15.8 %); 2010 (26.9 %), 2011(15.8 %) and 2012 (22.8 %). Cardiothoracic unit recorded highest death rate of 6.00%. About 132 (77.2 %) of the patients died within 1 month on admission. The leading causes of mortality were cancer of prostate 50(29.2 %) and breast cancer 40(23.4 %). Most of the deaths (42.2 %) occurred between 50 and 70 years old.Conclusion: Prostate, breast, and gastro-intestinal cancers constitute a great deal of health burden in our region. Early detection and timely interventions will be needed to reduce this burden.Keywords: Cancer, Surgical wards, Mortality, Tertiary hospital, Nigeria

Published
2016

12. What experts think about prostate cancer management during the COVID-19 pandemic: report from The Advanced Prostate Cancer Consensus Conference 2021

Author

Fabio Turco, Andrew Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline Clarke, Noel Clarke, Ian D. Davis, Johann de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celestia Higano, Michael S. Hofman, Maha Hussain, Nicholas James, Rob Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Christopher Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Ngozi Ekeke Onyeanunam, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Christopher Parker, Darren M.C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Türkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Silke Gillessen, Aurelius Omlin, Tilki, Derya, Turco, F., Armstrong, A., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Chi, K.N., Clarke, C.S., Clarke, N., Davis, I.D., de Bono, J., Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Evans, C.P., Fanti, S., Feng, F.Y., Fizazi, K., Frydenberg, M., George, D., Gleave, M., Halabi, S., Heinrich, D., Higano, C., Hofman, M.S., Hussain, M., James, N., Jones, R., Kanesvaran, R., Khauli, R.B., Klotz, L., Leibowitz, R., Logothetis, C., Maluf, F., Millman, R., Morgans, A.K., Morris, M.J., Mottet, N., Mrabti, H., Murphy, D.G., Murthy, V., Oh, W.K., Ekeke, O.N., Ost, P., O'Sullivan, J.M., Padhani, A.R., Parker, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M., Ryan, C.J., Saad, F., Sade, J.P., Sartor, O., Scher, H.I., Shore, N., Skoneczna, I., Small, E., Smith, M., Soule, H., Spratt, D.E., Sternberg, C.N., Suzuki, H., Sweeney, C., Sydes, M.R., Taplin, M.-E., Tombal, B., Türkeri, L., Uemura, H., van Oort, I., Yamoah, K., Ye, D., Zapatero, A., Gillessen, S., Omlin, A., Koç University Hospital, School of Medicine, Acibadem University Dspace, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, and UCL - (SLuc) Service d'urologie

Subjects
Male, COVID-19 Vaccines, Prostate cancer, Urology, COVID-19 boost injection, COVID-19 pandemic, COVID-19 vaccine, Prostate cancer management, Telemedicine, COVID-19, Prostatic Neoplasms, Androgen Antagonists, 610 Medicine & health, Urology and nephrology, SDG 3 - Good Health and Well-being, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Humans, Pandemics
Abstract

Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients., NA

Published
2022
Full Text
View/download PDF

13. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021

Author

Silke Gillessen, Andrew Armstrong, Gert Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Robert G. Bristow, Muhammad Bulbul, Orazio Caffo, Kim N. Chi, Caroline S. Clarke, Noel Clarke, Ian D. Davis, Johann S. de Bono, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Karim Fizazi, Mark Frydenberg, Dan George, Martin Gleave, Susan Halabi, Daniel Heinrich, Celesta Higano, Michael S. Hofman, Maha Hussain, Nick James, Robert Jones, Ravindran Kanesvaran, Raja B. Khauli, Laurence Klotz, Raya Leibowitz, Chris Logothetis, Fernando Maluf, Robin Millman, Alicia K. Morgans, Michael J. Morris, Nicolas Mottet, Hind Mrabti, Declan G. Murphy, Vedang Murthy, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Rob E. Reiter, Mark Rubin, Charles J. Ryan, Fred Saad, Juan P. Sade, Oliver Sartor, Howard I. Scher, Neal Shore, Iwona Skoneczna, Eric Small, Matthew Smith, Howard Soule, Daniel E. Spratt, Cora N. Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Bertrand Tombal, Levent Türkeri, Hiroji Uemura, Hirotsugu Uemura, Inge van Oort, Kosj Yamoah, Dingwei Ye, Almudena Zapatero, Aurelius Omlin, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service d'urologie, Acibadem University Dspace, Gillessen, Silke, Armstrong, Andrew, Attard, Gert, Beer, Tomasz M, Beltran, Himisha, Bjartell, Ander, Bossi, Alberto, Briganti, Alberto, Bristow, Robert G, Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N, Clarke, Caroline S, Clarke, Noel, Davis, Ian D, de Bono, Johann S, Duran, Ignacio, Eeles, Ro, Efstathiou, Eleni, Efstathiou, Jason, Ekeke, Onyeanunam Ngozi, Evans, Christopher P, Fanti, Stefano, Feng, Felix Y, Fizazi, Karim, Frydenberg, Mark, George, Dan, Gleave, Martin, Halabi, Susan, Heinrich, Daniel, Higano, Celesta, Hofman, Michael S, Hussain, Maha, James, Nick, Jones, Robert, Kanesvaran, Ravindran, Khauli, Raja B, Klotz, Laurence, Leibowitz, Raya, Logothetis, Chri, Maluf, Fernando, Millman, Robin, Morgans, Alicia K, Morris, Michael J, Mottet, Nicola, Mrabti, Hind, Murphy, Declan G, Murthy, Vedang, Oh, William K, Ost, Piet, O'Sullivan, Joe M, Padhani, Anwar R, Parker, Chri, Poon, Darren M C, Pritchard, Colin C, Rabah, Danny M, Rathkopf, Dana, Reiter, Rob E, Rubin, Mark, Ryan, Charles J, Saad, Fred, Sade, Juan P, Sartor, Oliver, Scher, Howard I, Shore, Neal, Skoneczna, Iwona, Small, Eric, Smith, Matthew, Soule, Howard, Spratt, Daniel E, Sternberg, Cora N, Suzuki, Hiroyoshi, Sweeney, Christopher, Sydes, Matthew R, Taplin, Mary-Ellen, Tilki, Derya, Tombal, Bertrand, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, van Oort, Inge, Yamoah, Kosj, Ye, Dingwei, Zapatero, Almudena, Omlin, Aurelius, Gillessen, S., Armstron, A., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Chi, K.N., Clarke, C.S., Clarke, N., Davis, I.D., de Bono, J.S., Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O.N., Evans, C.P., Fanti, S., Feng, F.Y., Fizazi, K., Frydenberg, M., George, D., Gleave, M., Halabi, S., Heinrich, D., Higano, C., Hofman, M.S., Hussain, M., James, N., Jones, R., Kanesvaran, R., Khauli, R.B., Klotz, L., Leibowitz, R., Logothetis, C., Maluf, F., Millman, R., Morgans, A.K., Morris, M.J., Mottet, N., Mrabti, H., Murphy, D.G., Murthy, V., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Parker, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M., Ryan, C.J., Saad, F., Sade, J.P., Sartor, O., Scher, H.I., Shore, N., Skoneczna, I., Small, E., Smith, M., Soule, H., Spratt, D.E., Sternberg, C.N., Suzuki, H., Sweeney, C., Sydes, M.R., Taplin, M.E., Tombal, B., Türkeri, L., Uemura, H., van Oort, I., Yamoah, K., Ye, D., Zapatero, A., Omlin, A., Koç University Hospital, and School of Medicine

Subjects
Male, Consensus, Urology, education, Lu-177-PSMA therapy, Consensu, Hormone-sensitive prostate cancer, Imaging, SDG 3 - Good Health and Well-being, Genetic, Lu-PSMA therapy, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Genetics, Humans, Castration-resistant prostate cancer, Tumour genomic profiling, Manchester Cancer Research Centre, Advanced prostate cancer, ResearchInstitutes_Networks_Beacons/mcrc, PARP inhibition, 177Lu-PSMA therapy, Next-generation sequencing, Prostate cancer treatment, Prostatic Neoplasms, Urology and nephrology, (177)Lu-PSMA therapy, Human
Abstract

Background: innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: to present the voting results from APCCC 2021. Design, setting, and participants: the experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: the voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: these voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identified salient questions that merit evaluation in specifically designed trials. Patient summary: the Advanced Prostate Cancer Consensus Conference is a forum for discussing current diagnosis and treatment options for patients with advanced prostate cancer. An expert panel votes on predefined questions focused on the most clinically relevant areas for treatment of advanced prostate cancer for which there are gaps in knowledge. The voting results provide a practical guide to help clinicians in discussing treatment options with patients as part of shared decision-making., National Health and Medical Research Council (NHMRC) Practitioner Fellowship; Prostate Cancer Foundation; Peter MacCallum Foundation; NHMRC Investigator Grant

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results